- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06706102
Temporal karaktärisering av extracellulära vesiklar under cellterapi med CAR-T-celler och under förekomsten av immuneffektorcell-associerat neurotoxicitetssyndrom (VESICANS)
Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS) is a common and serious neurological complication associated with the use of CAR-T cells. The mechanisms involved are still poorly understood but studies suggest that inflammation during treatment leads to an increase in the permeability of the barrier between the brain and the blood vessels and the emission of extracellular vesicles (EVs) circulating between the brain and the blood vessels. EVs are biological particles that play an important role in cellular communication and the modulation of several physiological processes. The VESICANS study aims to characterize the EVs released before and during CAR-T cells treatment and upon the occurrence of ICANS, using flow cytometry, electron microscopy, Nanoparticle Tracking Analysis associated with MRI assessment of the barrier between the brain and blood. This study will ultimately contribute to facilitating the prevention and treatment of this toxicity which affects the prognosis of patients.
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 4
Kontakter och platser
Studiekontakt
- Namn: Emilie CHALAYER, MD
- Telefonnummer: +33 (0)4 77 82 28 14
- E-post: emilie.chalayer@chu-st-etienne.fr
Studera Kontakt Backup
- Namn: Hélène RAINGARD
- Telefonnummer: +33 (0)4 77 82 97 03
- E-post: helene.raingard@chu-st-etienne.fr
Studieorter
-
-
-
Saint-Etienne, Frankrike, 42055
- Rekrytering
- CHU de Saint-Etienne
-
Underutredare:
- Ludovic FOUILLET, MD
-
Underutredare:
- Emmanuelle TAVERNIER, MD
-
Kontakt:
- Emilie CHALAYER, MD
- Telefonnummer: 33 (0)4 77 82 28 14
- E-post: emilie.chalayer@chu-st-etienne.fr
-
Underutredare:
- Jérôme CORNILLON, MD
-
Underutredare:
- Manon SAPET, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patient aged over 18,
- Patient for whom CAR-T treatment is indicated,
- Patient affiliated to a social security system
- Patient who give his consent to participate in the study.
Exclusion Criteria:
- Pregnant or breastfeeding woman,
- Patient unable to understand informed consent,
- Patient under legal protection.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: CAR T cell treatment
Major patients for whom CAR-T treatment is indicated. |
Biological tests : cell quantification et characterization MRI Neuropsychological tests |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Endothelial EVs quantification (EVs/mL)
Tidsram: Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
Quantification by Nano Tracking Analysis of endothelial EVs as a function of time before and after treatment with CAR-T cells according to ICANS grade. |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
Endothelial EVs characterization (immunophenotyping)
Tidsram: Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
Characterization by Nano Tracking Analysis (immunophenotyping by size) of endothelial EVs as a function of time before and after treatment with CAR-T cells according to ICANS grade. |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Other EV subtypes quantification (EV subtype/mL)
Tidsram: Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
Other EV subtypes quantification of as a function of time before and after treatment with CAR-T cells according to ICANS grade. |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
Other EV subtypes characterization (immunophenotyping)
Tidsram: Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
Other EV subtypes characterization of as a function of time before and after treatment with CAR-T cells according to ICANS grade. |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
EVS quantification according to the presence of an ICANS versus no ICANS (EV/mL)
Tidsram: Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
EVS quantification according to the presence of an ICANS versus no ICANS |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
EVs characterization according to the presence of an ICANS versus no ICANS (immunophenotyping)
Tidsram: Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
EVS characterization of EVs according to the presence of an ICANS versus no ICANS |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
EVs quantification according to levels of cytokines (EVs/mL)
Tidsram: Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
EVs quantification according to levels of cytokines |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
EVs characterization according to levels of cytokines
Tidsram: Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
EVs characterization according to levels of cytokines |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
EVs quantification in cerebrospinal fluid (EVs/mL)
Tidsram: Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
EVs quantification after treatment with CAR-T cells in cerebrospinal fluid (CSF) if available. |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
EVs characterization in cerebrosinalfluid.
Tidsram: Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
EVs characterization of EVs after treatment with CAR-T cells in cerebrospinal fluid (CSF) if available. |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
Association of EVs subpopulations in clinical neurological damage and sleep apnea syndrome.
Tidsram: Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
Characterization of the association of subpopulations of EVs according to clinical neurological damage and sleep apnea syndrome. |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
Association of EVs subpopulations in neuropsychological test and RMI.
Tidsram: Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
Characterization of the association of subpopulations of EVs according to neuropsychological test and RMI. |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
|
Cerabral involvement on RMI
Tidsram: Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
Diffusion tensor imaging and resting state default mode network |
Days -7, 0, 1, 2, 5, 8, 15, 30 and 60
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Emilie CHALAYER, MD, Centre Hospitalier Universitaire de Saint Etienne
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- 24CH009
- 2024-515328-35-00 (Ctis)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .